Thanks to PBMs’ efforts to give patients an incentive to use them and pharmacies an incentive to purchase them at the lowest prices, generics are widely available and affordable for hundreds of millions of Americans.

Using data from CMS, we see increases in the average plan contract-level beneficiary adherence to hypertension medication. Gains in adherence translates to real people staying on their medications and having better health outcomes.

This blog introduces a new series of blog posts that will look at interesting trends using the CMS’s historical Part D Star Ratings data, focusing on four measures of prescription drug adherence.

New report from the Congressional Budget Office highlights the value of PBMs in keeping net drug costs low for payers and patients.

Pharmacy Benefit Managers reduce prescription drug costs for patients and use innovative technology to help patients get their prescriptions and lead healthier lives.

High spending on prescription drugs with both orphan and non-orphan indications suggest potential misuse of Orphan Drug Act designations.

Using a gold-standard pharmacy dataset from the National Council for Prescription Drug Programs (NCPDP) and a transparent methodology, PCMA produces credible research with a clear conclusion: there are more independent pharmacies now than any time over the last decade.

Paying pharmacies more for dispensing medications will raise prescription drug costs without improving value.

Biosimilars play an important role in lowering net costs.

PBMs leverage competition between drugs to create savings for patients.

Patent thickets are a drug manufacturer’s strategy that keeps competitor products off the market and reduces PBMs’ ability to negotiate savings.